Band 3
Provided by Stephen R Auten
Intellectual Property Litigation
Pharmaceutical and Life Sciences Litigation
Intellectual Property Licensing
Chicago-Kent College of Law
J.D.
1997
Steve is head of Taft’s Pharmaceutical & Life Sciences Litigation practice area. He is a widely recognized and seasoned attorney in Hatch-Waxman and biosimilar matters, including related patent litigation, and is followed by key industry leaders (brand and generic alike), law firms, analysts, educators, and others on his LinkedIn blog “Hatch Waxman ANDA Litigation Forum” or HALF, which has over 14,000 members worldwide. He currently represents clients primarily in the areas of Paragraph IV design strategies, Hatch-Waxman litigation, and biosimilar market opportunities.
Steve is currently counsel to a number of leading generics, including those who are first-to-file with an ANDA with a Paragraph IV Certification, and thus eligible for 180-days of market exclusivity. Though he has litigated scores of ANDA cases, his current cases include generic versions of the following products: ANGIOMAX (bivalirudin), AXIRON (testosterone), BELVIQ (lorcaserin), DALIRESP (roflumilast), ELIQUIS (apixaban), FANAPT (iloperidone), JEVTANA KIT (cabazitaxel), KYPROLIS (carfilzomib), POMALYST (pomalidomide), STIVARGA (regorafenib), TEFLARO (ceftaroline fosamil), VIIBRYD (vilazodone), XARELTO (rivaroxaban), and XELJANZ (tofacitinib).
Provided by Chambers
Stephen Auten is the head of the pharmaceutical and life sciences litigation group at Taft. He routinely represents clients in patent disputes in the generic drugs space, including ANDA litigation.
Provided by Chambers
